SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
BMY (bristol myers squibb)
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
194 21 0 BMY
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
144BMY reported solid 2Q results. On 214 front,.....nothing new. Maybe idea is firsMiljenko Zuanic-7/26/2018
143RE: NKTR CEO own ~220K shares, however did not waste any time to unload 3 x 4333Miljenko Zuanic-6/28/2018
142If someone plot CM-227 (High TMB) chemo KM OS line on KN-189 OS KM plots, there Miljenko Zuanic-4/16/2018
141I voted "VO-DO". New-comers anti-PD1 may bring some clarity!!!???Miljenko Zuanic-4/16/2018
140No one seems to know the answer. I just voted in Matt Herper's survey by selDewDiligence_on_SI-4/16/2018
139Pem-Nivo gap (NSCLC) is wide open now. So, the Qs are WHY! What is secondary (ofMiljenko Zuanic-4/16/2018
138Now that Novatris has a deal how long will it be before PFE or BMY buys out LDS?james flannigan-3/19/2018
137I would go with neutral, with combo shoving trend toward survival benefit. HowevMiljenko Zuanic-3/12/2018
136Strangely, all biotech tweeps on my Twitter stream are saying the MYSTIC delay DewDiligence_on_SI-3/12/2018
135fiercepharma.com If delay in OS-read out is indicator for Imf. + tremelimumab Miljenko Zuanic-3/12/2018
134One do not need to be "Salamon" to figure out that hTMB will hurt respMiljenko Zuanic-2/5/2018
133While TMB per se is not BS, some of the stuff BMY said about TMB in the context DewDiligence_on_SI-2/5/2018
132IMO, Eliquis is not sufficient. It is shared with PFE. They are investing $$$$ Miljenko Zuanic-2/5/2018
131Ex-US, Opdivo still has a formidable advantage relative to Keytruda in reimburseDewDiligence_on_SI-2/5/2018
130From JPM notes: <Regarding IO... - Opdivo sales for 4Q were $1,361M (cons $Miljenko Zuanic-2/5/2018
129Still can not explain why so much difference in activity (for NSCLC) between OpdMiljenko Zuanic-2/5/2018
128What kind of F-ing SHIT is this: <The Opdivo plus Yervoy combination cohort iMiljenko Zuanic-1/21/2018
127I want to thanks all those who shorted at 2Q-results, so give me a chance to addMiljenko Zuanic-8/29/2017
126Not to forget that marker analysis and prediction of the response magnitude (RR Miljenko Zuanic-7/27/2017
125In light of the MISTIC failure (for PDL1>25%, NSCLC), maybe it is premature tMiljenko Zuanic-7/27/2017
124Bullish crossover in MACD and Stochastic oscillator. [graphic]hollyhunter-7/4/2017
123Agreed (eom).DewDiligence_on_SI-6/15/2017
122After listening Thomas Lynch presentation at GS, I become confident that he kMiljenko Zuanic-6/14/2017
121 AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers SZoro99-8/15/2016
120Bristol-Myers Squibb ($BMY +1.87%) was upgraded to 'Buy' from 'Neutrmore100-12/3/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News